Inventiva S.A./€IVA
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Inventiva S.A.
Inventiva S.A. is a clinical-stage biopharmaceutical company based in France, focused on developing oral small molecule therapies for the treatment of diseases with unmet medical needs, particularly in the areas of fibrosis, lysosomal storage disorders, and oncology. The company’s leading product candidate is lanifibranor, which is currently in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). Founded in 2012, Inventiva leverages its proprietary technology platform to identify and develop innovative compounds. The company's research and development operations are concentrated in Daix, France. Inventiva’s competitive strength lies in its robust pipeline and strategic collaborations with partners in the pharmaceutical industry. Sources:
1. https://inventivapharma.com/en/
2. https://ir.inventivapharma.com/
3. https://www.wallstreet-online.de/nachricht/14672309-inventiva-reports-financial-results-quarter-ended-september-30-2021
Ticker
€IVA
Sector
Primary listing
PAR
Employees
116
Headquarters
Website
Inventiva S.A. Metrics
BasicAdvanced
€644M
-
-€3.08
0.61
-
Price and volume
Market cap
€644M
Beta
0.61
52-week high
€5.48
52-week low
€1.43
Average daily volume
12K
Financial strength
Current ratio
0.924
Quick ratio
0.903
Long term debt to equity
-95.626
Total debt to equity
-169.953
Interest coverage (TTM)
-1.13%
Profitability
EBITDA (TTM)
-96.695
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-1,251.10%
Operating margin (TTM)
-662.57%
Effective tax rate (TTM)
-0.17%
Revenue per employee (TTM)
€130,000
Management effectiveness
Return on assets (TTM)
-63.60%
Return on equity (TTM)
265.67%
Valuation
Price to revenue (TTM)
19.68
Price to book
-4.15
Price to tangible book (TTM)
-4.15
Price to free cash flow (TTM)
-3.216
Free cash flow yield (TTM)
-31.10%
Free cash flow per share (TTM)
-1.443
Growth
Revenue change (TTM)
-38.24%
Earnings per share change (TTM)
26.56%
3-year revenue growth (CAGR)
18.36%
10-year revenue growth (CAGR)
8.64%
3-year earnings per share growth (CAGR)
34.47%
10-year earnings per share growth (CAGR)
15.22%
Bulls say / Bears say
Inventiva completed enrollment in its pivotal Phase 3 NATiV3 trial on April 1, 2025, reducing the program’s risk and meeting key conditions for further funding (GlobeNewswire turn0search1)
On May 5, 2025, Inventiva secured €115.6 million gross (€108.5 million net) in the second tranche of its structured financing, extending its cash runway through the end of Q3 2026 (Nasdaq turn5search0)
In February 2025, Inventiva and Hepalys began a Phase 1 trial of lanifibranor in Japan, broadening the program’s geographic scope and paving the way for regulatory filings in Asia (BioSpace turn0search4)
Inventiva reported no revenues for Q1 2025, highlighting its ongoing reliance on external capital rather than product sales (Reuters turn4search4)
The company’s February 2025 pipeline prioritization entails cutting its workforce by 50% as of May 23, 2025, risking reduced R&D capacity and fewer future programs (Reuters turn4search4)
The second tranche of the structured financing includes a large number of warrants and instruments; if fully exercised, they could dilute existing shareholders by up to 46.4%, significantly lowering current stakes (Nasdaq turn5search1)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Inventiva S.A. stock?
Inventiva S.A. (IVA) has a market cap of €644M as of September 14, 2025.
What is the P/E ratio for Inventiva S.A. stock?
The price to earnings (P/E) ratio for Inventiva S.A. (IVA) stock is 0 as of September 14, 2025.
Does Inventiva S.A. stock pay dividends?
No, Inventiva S.A. (IVA) stock does not pay dividends to its shareholders as of September 14, 2025.
When is the next Inventiva S.A. dividend payment date?
Inventiva S.A. (IVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Inventiva S.A.?
Inventiva S.A. (IVA) has a beta rating of 0.61. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.